Drug Profile
CLBS 03
Alternative Names: CD4+CD127lo/-CD25+ polyclonal Treg adoptive immunotherapy; CD4+CD127lo/-CD25+ polyclonal Tregs; CLBS03; Ex vivo expanded human autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cells; NBS 03; NBS03A; NBS03D; NSB-03; NSB-03A; NSB-03D; Regulatory T cell therapy - Athelos Corporation/Becton, Dickinson and Company; Regulatory T lymphocyte cell therapy - Athelos; T cell replacement therapy - Athelos Corporation/Becton, Dickinson and Company; Treg cells - Lisata TherapeuticsLatest Information Update: 19 Sep 2022
Price :
$50
*
At a glance
- Originator Becton, Dickinson and Company
- Developer Athelos Corporation; Becton, Dickinson and Company; Lisata Therapeutics; Sanford Health; University of California at San Francisco
- Class Antiasthmatics; Antihyperglycaemics; Regulatory T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Type 1 diabetes mellitus
- No development reported Asthma; Graft-versus-host disease; Multiple sclerosis; Systemic lupus erythematosus; Transplant rejection
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 27 Sep 2021 CLBS 03 is still in phase II trials for Type-I diabetes mellitus (In adolescents) in USA (IV) (NCT02691247)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Type-1 diabetes mellitus in Poland (IV, Infusion)